HER2 Positive BC - Study of Tucatinib vs Placebo With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.

Learn more at Clinicaltrials.gov NCT02614794